98 related articles for article (PubMed ID: 8137729)
21. In vitro 3,5,3'-triiodothyronine binding to rat cerebrocortical neuronal and glial nuclei suggests the presence of binding sites unavailable in vivo.
Kolodny JM; Larsen PR; Silva JE
Endocrinology; 1985 May; 116(5):2019-28. PubMed ID: 2985367
[TBL] [Abstract][Full Text] [Related]
22. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene.
Bakker O; Hudig F; Meijssen S; Wiersinga WM
Biochem Biophys Res Commun; 1998 Aug; 249(2):517-21. PubMed ID: 9712728
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor decreases thyroid hormone receptors and attenuates thyroid hormone responses in GH4C1 cells.
Kaji H; Hinkle PM
Endocrinology; 1987 Feb; 120(2):537-43. PubMed ID: 3492366
[TBL] [Abstract][Full Text] [Related]
24. The effect of endocrine disrupting chemicals on thyroid hormone binding to Japanese quail transthyretin and thyroid hormone receptor.
Ishihara A; Nishiyama N; Sugiyama S; Yamauchi K
Gen Comp Endocrinol; 2003 Oct; 134(1):36-43. PubMed ID: 13129501
[TBL] [Abstract][Full Text] [Related]
25. Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence.
Van Beeren HC; Jong WM; Kaptein E; Visser TJ; Bakker O; Wiersinga WM
Endocrinology; 2003 Feb; 144(2):552-8. PubMed ID: 12538616
[TBL] [Abstract][Full Text] [Related]
26. Amiodarone antagonizes the effects of T3 at the receptor level: an additional mechanism for its in vivo hypothyroid-like effects.
Paradis P; Lambert C; Rouleau J
Can J Physiol Pharmacol; 1991 Jun; 69(6):865-70. PubMed ID: 1913332
[TBL] [Abstract][Full Text] [Related]
27. Preparation of unoccupied thyroid-hormone receptor.
Li Q; Inoue A
Biochem J; 1994 Jan; 297 ( Pt 1)(Pt 1):75-8. PubMed ID: 7506534
[TBL] [Abstract][Full Text] [Related]
28. Subcellular localization and binding of 125I-triiodothyronine in calf thyroid.
Pisarev MA; Juvenal GJ; Kleiman de Pisarev DL; Chazenbalk GD; Krawiec L; Valsecchi RM
Horm Metab Res; 1986 May; 18(5):318-22. PubMed ID: 3013744
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of thyroid hormone action by 1,25-dihydroxyvitamin D3 in pituitary cells.
Kaji H; Hinkle PM
Endocrinology; 1989 Feb; 124(2):930-6. PubMed ID: 2463908
[TBL] [Abstract][Full Text] [Related]
30. Characterization of cytoplasmic T3 binding sites by adsorption to hydroxyapatite: effects of drug inhibitors of T3 and relationship to glutathione-S-transferases.
Barlow JW; Raggatt LE; Lim CF; Topliss DJ; Stockigt JR
Thyroid; 1992; 2(1):39-44. PubMed ID: 1326362
[TBL] [Abstract][Full Text] [Related]
31. Competitive inhibition of T3 binding to alpha 1 and beta 1 thyroid hormone receptors by fatty acids.
van der Klis FR; Schmidt ED; van Beeren HC; Wiersinga WM
Biochem Biophys Res Commun; 1991 Sep; 179(2):1011-6. PubMed ID: 1654895
[TBL] [Abstract][Full Text] [Related]
32. In vitro binding of L-triiodothyronine to receptors in rat liver nuclei. Kinectics of binding, extraction properties, and lack of requirement for cytosol proteins.
Surks MI; Koerner DH; Oppenheimer JH
J Clin Invest; 1975 Jan; 55(1):50-60. PubMed ID: 162784
[TBL] [Abstract][Full Text] [Related]
33. Amiodarone reduces the effect of T3 on beta adrenergic receptor density in rat heart.
Hartong R; Wiersinga WM; Plomp TA
Horm Metab Res; 1990 Feb; 22(2):85-9. PubMed ID: 2157654
[TBL] [Abstract][Full Text] [Related]
34. Thyroid hormone control of thyrotropin gene expression in rat anterior pituitary cells.
Shupnik MA; Ridgway EC
Endocrinology; 1987 Aug; 121(2):619-24. PubMed ID: 2439318
[TBL] [Abstract][Full Text] [Related]
35. Binding of thyroid hormones to nuclear extracts of thyroid cells.
Erkenbrack DE; Rosenberg LL
Endocrinology; 1986 Jul; 119(1):311-7. PubMed ID: 3013592
[TBL] [Abstract][Full Text] [Related]
36. Comparison of thyroid hormone binding to heptic nuclei of the rat and a teleost (Oncorhynchus kisutch).
Darling DS; Dickhoff WW; Gorbman A
Endocrinology; 1982 Dec; 111(6):1936-43. PubMed ID: 7140642
[TBL] [Abstract][Full Text] [Related]
37. Abnormalities of triiodothyronine binding to lymphocyte and fibroblast nuclei from a patient with peripheral tissue resistance to thyroid hormone action.
Bernal J; Refetoff S; DeGroot LJ
J Clin Endocrinol Metab; 1978 Dec; 47(6):1266-72. PubMed ID: 233694
[TBL] [Abstract][Full Text] [Related]
38. Modulation of protein kinase C activity by amiodarone and desethylamiodarone.
Vig PJ; Desaiah D
Neurotoxicology; 1991; 12(3):595-601. PubMed ID: 1745442
[TBL] [Abstract][Full Text] [Related]
39. The thyroid hormone receptor variant alpha2 is a weak antagonist because it is deficient in interactions with nuclear receptor corepressors.
Tagami T; Kopp P; Johnson W; Arseven OK; Jameson JL
Endocrinology; 1998 May; 139(5):2535-44. PubMed ID: 9564869
[TBL] [Abstract][Full Text] [Related]
40. Differential regulation of thyroid hormone receptor messenger ribonucleic acid levels by thyrotropin-releasing hormone.
Jones KE; Chin WW
Endocrinology; 1991 Apr; 128(4):1763-8. PubMed ID: 1900776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
